New drug combo aims to outperform standard chemo in lung cancer
Disease control
Not yet recruiting
This phase 3 study tests whether a new drug (HS-20093) combined with an immunotherapy (adebrelimab) works better than standard chemotherapy (docetaxel) for people with advanced non-squamous non-small cell lung cancer that has already been treated. About 450 adults will be randoml…
Phase: PHASE3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated May 17, 2026 11:53 UTC